Aptahem Launches US Stock Market Listing Process to Fund Clinical Trials

Aptahem has officially initiated the process for listing its shares on a US stock exchange, a strategic move aimed at enhancing its financing conditions for the upcoming phase 2 clinical study of its drug candidate, Apta-1. This announcement was publicly disclosed through a press release on August 26, 2025, underscoring Aptahem's commitment to expanding its reach in the pharmaceutical market and securing necessary funding for its research initiatives.

The planned US listing reflects Aptahem’s ambition to bolster its presence in the international market, particularly as it prepares to advance its clinical trials. The company aims to tap into the larger investor base and capital opportunities available in the United States, which can be critical for the successful progression of its drug development efforts.